Gan & Lee Pharmaceuticals
Manufacturing · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
通州区漷 8 县, Beijing, ChinaPhone Number
+86 1056965000Website
www.ganlee.comRevenue
$8.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Gan & Lee Pharmaceuticals
Gan & Lee Pharmaceuticals is a global pharmaceutical company dedicated to improving human health by delivering high-quality medicines and services. The company focuses on innovation and commercialization in areas such as diabetes, oncology, and medical devices. With a presence in 23 countries and a commitment to global business development, Gan & Lee aims to expand its impact worldwide. Their intended clients include patients and healthcare professionals seeking effective treatment options.Explore more
Gan & Lee Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gan & Lee Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Gan & Lee Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Gan & Lee Pharmaceuticals has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Gan & Lee Pharmaceuticals is spiking on competitors!
Check if Gan & Lee Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if Gan & Lee Pharmaceuticals had a recent Job posting/layoffs
Earning: See what the market has to say on Gan & Lee Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Gan & Lee Pharmaceuticals
Product Launch: Get notified when Gan & Lee Pharmaceuticals launches new products
Recommended Actions
Find VP level buyers at Gan & Lee Pharmaceuticals
Find 2 more new buyers
Company Profile Activity
Activity Insights
Gan & Lee Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Gan & Lee Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Gan & Lee Pharmaceuticals.
Gan & Lee Pharmaceuticals financials insights
Gather financial insights about Gan & Lee Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$363.8M
Gan & Lee Pharmaceuticals Tech Stack
A closer look at the technologies used by Gan & Lee Pharmaceuticals
Most Recent Scoops
Open Position
Open Position
Hiring Plans
Gan & Lee Pharmaceuticals has more open roles in Legal than it has had at any time in the past 12 months. Technologies mentioned include: JazzHR. Areas of expertise include: Regulatory Affairs Certification (RAC), Regulatory CMC, Regulatory Filings, Regulatory Compliance, and Regulatory Developments.
Hiring Plans
Open Position
Open Position
Gan & Lee Pharmaceuticals News & Media
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
BEIJING and BRIDGEWATER, N.J., June 12, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (hereinafter "Gan & Lee", stockcode: 603087.SH) announced that two of its core pipeline products in the fields of diabetes and obesity treatment have recently achieved positive clinical results....Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation
Gan & Lee will receive a $5m upfront payment plus up to $76.1m in milestone payments.Gan & Lee begins Phase III GLP-1 RA clinical trial in China
The GRADUAL clinical development programme comprises three Phase III studies, targeting over 1,000 subjects in China.Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
BEIJING, Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Gan & Lee Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Gan & Lee Pharmaceuticals is a global pharmaceutical company dedicated to improving human health by delivering high-quality medicines and services. The company focuses on innovation and commercialization in areas such as diabetes, oncology, and medical devices. With a presence in 23 countries and a commitment to global business development, Gan & L... Read More
